CNN1 Antibody

What is CNN1 and why is it an important research target?

CNN1 (Calponin 1) is a protein encoded by the CNN1 gene in humans, with a canonical length of 297 amino acid residues and a mass of approximately 33.2 kDa. It belongs to the Calponin protein family and plays a crucial role in muscle contraction. CNN1 is also known by several other names including SMCC, Sm-Calp, basic calponin, calponin H1, and HEL-S-14 .

CNN1 is particularly important as a research target due to its role as a marker for various cell types, including Vascular Smooth Muscle Cells, Bronchus Submucosal Gland Myoepithelial Cells, Bronchial Smooth Muscle Cells, Tracheobronchial Smooth Muscle Cells, and Bronchiolar Smooth Muscle Cells . Additionally, recent studies have identified CNN1's potential prognostic value in various cancers and its correlation with angiogenesis and immune checkpoints, making it an increasingly important target in cancer research .

What types of CNN1 antibodies are available for scientific research?

CNN1 antibodies are available in various formats to accommodate different research applications:

Researchers should select antibodies based on their specific application requirements. For instance, monoclonal antibodies offer high specificity to a single epitope, while polyclonal antibodies can provide greater sensitivity by recognizing multiple epitopes . Some antibodies, such as the rabbit polyclonal antibody against the N-terminal region of CNN1, demonstrate cross-reactivity across multiple species including human, rat, mouse, cow, dog, horse, pig, sheep, and zebrafish, which can be valuable for comparative studies .

What are the validated applications for CNN1 antibodies?

CNN1 antibodies have been validated for numerous research applications as shown below:

For Western blotting specifically, CNN1 typically appears as a band around 40 kDa under reducing conditions . When performing immunohistochemistry, heat-induced epitope retrieval is often necessary for optimal staining results, as demonstrated in protocols for human small intestine tissue sections .

How should I validate the specificity of a CNN1 antibody for my research?

Validating antibody specificity is crucial for ensuring reliable research results. For CNN1 antibodies, consider the following validation approaches:

• Positive control testing: Use cell lines known to express CNN1, such as MDA-MB-231 or MCF-7 human breast cancer cell lines, NMuMG mouse mammary gland epithelial cells, or A7r5 rat thoracic aortic smooth muscle cells .

• Western blot analysis: Confirm a single specific band at approximately 40 kDa under reducing conditions .

• Immunocytochemistry/Immunohistochemistry: Compare staining patterns with known CNN1 distribution, such as cytoplasmic localization in smooth muscle cells of human small intestine .

• Cross-reactivity assessment: If working with non-human samples, verify predicted reactivity levels. For example, some CNN1 antibodies show 100% reactivity with human, mouse, rat, cow, dog, and horse proteins, but slightly lower reactivity with pig (93%) and zebrafish (77%) .

• Knockout/knockdown controls: When possible, use CNN1 knockout or knockdown samples as negative controls to confirm specificity.

What is the relationship between CNN1 expression and cancer progression?

Recent research has revealed complex patterns of CNN1 expression across different cancer types. Analysis using multiple databases (TIMER, UALCAN, and GEPIA) has shown that CNN1 expression is aberrantly regulated in various cancers, with distinct patterns:

These expression patterns suggest that CNN1 may play different roles depending on the cancer context. Interestingly, CNN1 expression positively correlates with angiogenesis markers and immune checkpoint genes in many cancer types, indicating potential involvement in tumor vascularization and immune evasion mechanisms .

Researchers investigating CNN1 in cancer should consider these tissue-specific differences when designing experiments and interpreting results.

How does CNN1 expression correlate with immune cell infiltration and immunotherapy potential?

CNN1 expression shows significant correlations with both immune subtypes and molecular subtypes across multiple cancer types. Research using the TISIDB database revealed correlations between CNN1 expression and immune subtypes in 18 different cancer types (ACC, BLCA, BRCA, CESC, HNSC, KICH, KIRC, LGG, LIHC, LUAD, LUSC, MESO, OV, PCPG, PRAD, SARC, STAD, and TGCT) .

Importantly, CNN1 expression correlates positively with numerous immune checkpoint genes in multiple cancers, particularly:

• LIHC (30 immune checkpoint genes positively correlated)

• PCGC (23 immune checkpoint genes positively correlated)

Additionally, CNN1 expression significantly correlates with immune cell infiltration in gastric cancer (STAD), further supporting its potential role in the tumor immune microenvironment .

What are the optimal protocols for detecting CNN1 in fixed tissue samples?

For optimal CNN1 detection in fixed tissue samples, the following protocol has been validated:

• Sample preparation: Use formalin-fixed, paraffin-embedded tissue sections.

• Epitope retrieval: Perform heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (pH 8.0-9.0), as CNN1 epitopes are often masked during fixation .

• Primary antibody incubation: Apply CNN1 antibody at 10-15 μg/mL concentration overnight at 4°C for optimal signal-to-noise ratio. For example, Mouse Anti-Human Calponin 1 Monoclonal Antibody has been successfully used at 15 μg/mL .

• Detection system: Use an appropriate detection system such as HRP-DAB (3,3'-diaminobenzidine) for chromogenic detection or fluorescent secondary antibodies for immunofluorescence.

• Counterstaining: Apply hematoxylin for chromogenic detection or DAPI for nuclear counterstaining in immunofluorescence.

This protocol has been validated for human small intestine tissue, where CNN1 staining localizes specifically to the cytoplasm of smooth muscle cells . When adapting this protocol to different tissue types, optimization of antibody concentration and incubation times may be necessary.

What approaches can be used to study CNN1's role in angiogenesis?

Given the correlation between CNN1 expression and angiogenesis identified in recent studies , researchers interested in exploring this relationship should consider the following methodological approaches:

• Co-expression analysis: Use gene set enrichment analysis (GSEA) to analyze the expression pattern of CNN1 and vascular endothelium growth factor (VEGF) in cancer samples, as demonstrated in recent research .

• Co-immunostaining: Perform dual immunofluorescence or immunohistochemistry for CNN1 and angiogenesis markers like CD31, VEGF, or VEGFR2 to visualize potential co-localization in tissue sections.

• Functional studies:

  • Use siRNA or CRISPR to knock down CNN1 in endothelial cells or cancer cells and assess effects on tube formation, migration, and other angiogenesis-related processes

  • Perform CNN1 overexpression experiments to determine if it enhances angiogenic potential

• In vivo models: Develop mouse models with CNN1 manipulation in tumors to evaluate impacts on tumor vascularization and growth.

• Pathway analysis: Investigate whether CNN1 interacts with key angiogenesis signaling pathways like VEGF/VEGFR, Notch, or Angiopoietin/Tie2 pathways.

How can CNN1 antibodies be incorporated into multiplex immunoassays?

Incorporating CNN1 antibodies into multiplex immunoassays requires careful consideration of antibody compatibility, fluorophore selection, and staining sequence:

• Antibody selection: Choose CNN1 antibodies raised in different host species than other target antibodies to avoid cross-reactivity. For example, if using rabbit antibodies for other targets, select a mouse anti-CNN1 antibody like MAB7900 .

• Fluorophore selection: For multiplex immunofluorescence, select fluorophores with minimal spectral overlap. CNN1 has been successfully detected using Northern-Lights™ 557-conjugated secondary antibodies , but can be adapted to other fluorophores based on the multiplex design.

• Sequential staining: For challenging multiplex protocols, consider sequential staining with stripping or quenching between rounds.

• Controls:

  • Single-stain controls to confirm antibody specificity and absence of bleed-through

  • Isotype controls to assess non-specific binding

  • Absorption controls using recombinant CNN1 protein

• Analysis approaches: Use spectral unmixing algorithms for confocal microscopy or multispectral imaging systems to accurately separate overlapping signals in complex multiplex protocols.

When combining CNN1 with other smooth muscle markers (e.g., α-SMA, SM22α) or cell type-specific markers, titrate each antibody individually before performing multiplex staining to ensure optimal signal-to-noise ratio.

What are common challenges in CNN1 antibody applications and how can they be addressed?

Researchers working with CNN1 antibodies may encounter several challenges that require troubleshooting:

When troubleshooting CNN1 detection specifically in vascular tissues, researchers should note that Calponin 1 is expressed predominantly in differentiated smooth muscle cells but may be downregulated in proliferating or synthetic phenotype VSMCs. This physiological regulation can lead to variable expression levels that might be misinterpreted as technical issues.

How can CNN1 antibodies be used to investigate smooth muscle differentiation?

CNN1 antibodies serve as valuable tools for studying smooth muscle differentiation due to CNN1's role as a marker of differentiated smooth muscle cells:

• Differentiation monitoring: Track smooth muscle differentiation by quantifying CNN1 expression over time using Western blot or immunofluorescence.

• Co-expression analysis: Combine CNN1 antibodies with antibodies against other smooth muscle markers with different temporal expression patterns:

  • Early markers: SM22α, SMA

  • Mid-stage markers: CNN1, SM-MHC

  • Late markers: Smoothelin, Desmin

• Stem cell differentiation: Monitor mesenchymal stem cell or iPSC differentiation into smooth muscle lineages using CNN1 as a differentiation marker.

• Phenotypic switching assessment: Evaluate smooth muscle phenotypic switching between contractile and synthetic states by monitoring CNN1 downregulation during the transition to a synthetic phenotype.

• Response to mechanical stimuli: Investigate how mechanical forces affect smooth muscle differentiation by analyzing CNN1 expression under different mechanical conditions.

For quantitative assessment of differentiation, researchers can perform Western blot analysis using CNN1 antibodies at 1 μg/mL, following protocols validated for A7r5 rat thoracic aortic smooth muscle cells as positive controls .

How is CNN1 being investigated as a potential prognostic or therapeutic target?

Recent research has highlighted CNN1's potential as both a prognostic marker and therapeutic target:

• Prognostic value: Analysis using the PrognoScan and Kaplan-Meier plot databases has revealed that CNN1 expression correlates with patient outcomes in various cancers . Researchers should consider incorporating CNN1 expression analysis into their prognostic signature development.

• Correlation with immune checkpoints: The strong positive correlation between CNN1 expression and immune checkpoint genes in most cancer types suggests that CNN1 could serve as a biomarker for immunotherapy response prediction .

• CNN1 inhibition: In sarcoma (SARC) and diffuse large B-cell lymphoma (DLBC), where CNN1 expression negatively correlates with immune checkpoint genes, CNN1 inhibitors might represent potential therapeutic strategies .

• Association with angiogenesis: CNN1's correlation with VEGF expression suggests it may influence tumor angiogenesis, opening potential avenues for anti-angiogenic therapy development .

Researchers exploring CNN1 as a therapeutic target should consider:

• Developing CNN1-targeting antibodies for therapy

• Investigating small molecule inhibitors of CNN1

• Exploring RNA interference approaches to modulate CNN1 expression

• Evaluating combination strategies with existing immunotherapies based on CNN1 expression profiles

What are the latest methodological advances in CNN1 detection and quantification?

Recent methodological advances have enhanced the sensitivity and application range of CNN1 detection:

• Recombinant antibody technology: Development of recombinant CNN1 antibodies (e.g., CNN1-1408R, rCNN1-832) offers improved lot-to-lot consistency and specialized applications .

• Multiplex immunofluorescence: Integration of CNN1 antibodies into multiplexed panels allows simultaneous visualization of multiple markers, enabling more comprehensive analysis of tissue microenvironments.

• Digital pathology approaches: Quantitative image analysis using whole slide imaging and artificial intelligence algorithms can provide objective quantification of CNN1 expression in tissue samples.

• Single-cell analysis: Application of CNN1 antibodies in single-cell techniques like mass cytometry (CyTOF) and CODEX enables high-dimensional analysis of CNN1 expression at the single-cell level.

• In situ hybridization combination: Dual detection of CNN1 mRNA and protein using RNAscope combined with immunohistochemistry provides insights into transcriptional and post-transcriptional regulation.

Researchers should evaluate these emerging methodologies based on their specific research questions and available resources, recognizing that traditional approaches like Western blotting and immunohistochemistry remain robust and well-validated for CNN1 detection in many applications.